Devyser secures a four-year tender in France for Devyser Compact
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in...
This paper by Dr. Agneta Wikman, Professor at Karolinska University Hospital explores an approach that uses non-invasive prenatal testing to determine the fetal RHD status, allowing targeted administration of antenatal anti-D prophylaxis only to those who will benefit from it. Learn more about the current strategies of fetal RHD and the experiences and considerations surrounding planning a fetal RHD screening program.
This paper by Dr. Agneta Wikman, Professor at Karolinska University Hospital explores an approach that uses non-invasive prenatal testing to determine the fetal RHD status, allowing targeted administration of antenatal anti-D prophylaxis only to those who will benefit from it. Learn more about the current strategies of fetal RHD and the experiences and considerations surrounding planning a fetal RHD screening program.
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in...
Read More
Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been...
Read More
Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its...
Read More
Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical...
Read More